Acquisitive Emergent BioSolutions buys PaxVax for $270M by Angus Liu Monday, August 13, 2018 PaxVax has two FDA-approved vaccines that could deliver about $70 million to $90 million to Emergent’s top line in 2019.
Dynavax, Emergent and more—News of Note by Angus Liu Wednesday, August 8, 2018 Here is some other vaccine news of note for the week.
GSK's Mosquirix, Emergent BioSolutions and more—News of Note by Angus Liu Wednesday, April 18, 2018 Here is some other vaccine news of note for the week.
